IKT - Inhibikase Therapeutics GAAP EPS of -$0.72 revenue of $0.1M

2023-03-31 08:52:50 ET

• Inhibikase Therapeutics press release ( NASDAQ: IKT ): FY GAAP EPS of -$0.72.
• Revenue of $0.1M (-96.8% Y/Y).
• Cash, cash equivalents and marketable securities were $23.1 million as of December 31, 2022.
• Selling, general and administrative expenses for the year ended December 31, 2022 were $6.2 million compared to $6.5 million for the year ended December 31, 2021.
• Research and development expenses were $12.0 million for the year ended December 31, 2022 compared to $11.4 million in the year ended December 31, 2021.

For further details see: